Oxford Instruments plc Report and Financial Statements 2013 22 Financial Review The diverse nature of the Group combined with its current financial strength provides asolid foundation fora sustainable business.
Trading performance Adjusted gross margins increased from Orders in the period were 334.0 million 44.2% to 44.7%.
Including inter-segment were predominantly due to new product trade, the split between segments was: introductions and increased efficiencies Nanotechnology Tools 166.6 million, up with our Value Add Index Key Performance 5.1%: Industrial Products 102.2 million, Indicator increasing from 1.49 to 1.55.
This down 17.2%: and Service 66.9 million, measure is a reflection of the adjusted up14.8%.
At the end of the year the Group operating profit generated from each unit order book for future deliveries stood at of employment costs.
The order book was reduced in the year by Adjusted operating expenses rose by 15.6 million of sales made to the ITER 3.7million, reflecting a 4.7 million spend project which had been booked as orders in newly acquired businesses and a in 2009 10.
1.3million benefit from foreign exchange Kevin Boyd rate movements.
On an underlying constant Group Finance Director Revenues in the year grew by 4.0% currency growth basis, adjusted operating to350.8 million.
The net increase in expenses increased by 0.3 million.
revenues due to acquisitions and disposals Revenue was 5.0 million compared with the prior Adjusted operating profit increased by period while adverse foreign currency 18.1% to 49.7 million with the adjusted exchange rate movements reduced sales operating profit margin rising from 12.5% 350.8m by 6.0 million.
4% Financial income and expenditure In Nanotechnology Tools, revenues Within financial income and expenditure, grew7.9% aided by the acquisition of the cost of interest on loans and Asylum in December 2012.
While we saw overdrafts and the commitment fee for Adjusted return on sales strong growth in both our NanoAnalysis our revolving credit facility, offset by and Plasma Technology businesses, deposit interest, amounted to 0.6 million revenues in the newly combined Omicron 2012: 0.8 million.
The interest charge 14.2% Nanoscience business were flat.
Constant on pension scheme liabilities exceeded currency organic growthwas 9.4%.
the expected return on pension scheme 1.7pp assets by 0.9 million, a movement of Following an excellent growth year in 1.6 million over the prior year.
Due to the Net cash 2011 12, revenues in Industrial Products increased pension liabilities at 31 March fell back by 3.1%.
On a constant currency 2013, combined with the changes in the organic basis, we saw growth of 1.4% IAS 19 accounting standard, the net with the fall in sales in our Austin pension charge to the Income Statement 39.2m Scientific business being compensated in 2013 14 is expected to increase to for by growth in superconducting wire 2.5million of which 2.2 million will be sales for MRI applications.
reported in financial expenditure and 0.3million in administration and shared Service revenues increased by 7.6%, due service costs.
to the Platinum business we acquired in November 2011.
Excluding this, constant The Group uses derivative products to currency organic revenues were flat with hedge its exposure to fluctuations in growth in the service revenues within foreign exchange rates.
It is Group policy Nanotechnology Tools and Industrial to have in place at the beginning of a Products being offset by a small reduction financial year hedging instruments to in revenues from our non-Platinum MRI cover 80% of its forecast transactional service business in North America.
Business Overview Business Review Corporate Governance Financial Statements Company Information 23 Oxford Instruments plc Report and Financial Statements 2013 Adjusted gross margin Adjusted operating profit 44.7% 49.7m 0.5pp 18.1% In common with a number of other Taxation forward tax losses.
In 2014 15 rates will companies, the Group has decided that The underlying tax rate on the profit therefore rise and we currently expect the additional costs of meeting the before tax for the Group before adjusting them to be in the region of 24%28%.
extensive documentation requirements items was unchanged at 21%.
of IAS 39 to apply hedge accounting to Earnings these foreign exchange hedges cannot The Group has brought forward tax losses After a tax charge of 7.6 million 2012: be justified.
Accordingly the Group does in the UK to offset against future taxable 11.3 million, the reported net profit for not use hedge accounting for these profits.
In the year ended March 2011, the financial year was 22.0 million 2012: derivatives.
Net movements on marking dueto the improved performance of the 24.8 million.
With a weighted average to market such derivatives at the balance Groups UK businesses, we recognised number of shares of 56.2 million 2012: sheet date are disclosed in the income adeferred tax asset of 11.3 million and 54.0 million, the basic earnings per share statement as Financial Expenditure and acorresponding credit to the Income were 39.2 pence 2012: 46.0 pence.
excluded from our calculation of adjusted Statement.
We believe that this was profit before tax Note 1. exceptional both in nature and quantum Adjusted profit before tax Note 1 grew and therefore excluded it from our by 6.2 million to 48.2 million which The Group also uses derivative products calculation of adjusted earnings per share.
equates to adjusted earnings per share of to hedge its exposure to fluctuations in Of this asset value, 3.3 million reversed 68.3 pence 2012: 61.6 pence, an increase the price of copper, a major component in the year ended March 2013 and to be of 10.9%.
for the Superconducting Wire business.
consistent we have excluded it from the Given the small number of contracts calculation of adjusted earnings per share involved, we apply hedge accounting for see Note 1.
In the 2013 14 financial year these transactions and consequently the we expect tax rates to be similar to results of marking to market are excluded 2012 13 as we exhaust these brought from the Income Statement.
Adjusting items The Directors believe that adjusted profit before tax gives a clearer indication of the underlying performance of the business.
Areconciliation of reported profit before tax to adjusted profit before tax is given below: 2013 2012 m m Profit before income tax 29.6 36.1 Reversal of acquisition related fair value adjustments toinventory 0.5 1.7 Gain on disposal of product line 7.0 Acquisition related costs 2.1 1.5 Amortisation and impairment of acquired intangibles 13.8 11.2 Unwind of discount in respect of deferred consideration 0.2 Mark to market loss gain in respect of derivative financialinstruments 2.0 1.5 Adjusted profit before income tax 48.2 42.0 Share of taxation 9.9 8.8 Adjusted profit for the year 38.3 33.2 Oxford Instruments plc Report and Financial Statements 2013 24 Financial Review continued The Directors have reviewed the Groupsforecasts and believe that theGroup is well placed to manage itsbusiness risks successfully.
Dividends Assets of the schemes at 31 March 2013 In 2011 the Group moved to a progressive were 198.0 million 2012: 180.2 million, Adjusted earnings per share dividend policy, whereby we would seek while liabilities increased from 215.4 million to raise dividends as adjusted earnings to 245.9 million principally as a result of per share rise, although not necessarily the fall in the corporate bond yield used 68.3p by the same proportion, depending on to discount future cash flows from 4.9% the Directors perceived need for cash to 4.5%.
11% toexpand the business both organically and through acquisition.
For the year just The latest triennial actuarial valuation ended the proposed final dividend of ofthe UK scheme was carried out as at Research and Development cash spend 8.15pence per share 2012: 7.23 pence, 31March 2012 and resulted in an actuarial payable on 24 October 2013 to shareholders deficit of 48.8 million.
A long term plan who are on the register on 27 September for recovering the deficit over eight years 25.1m 2013, gives a total dividend for the year has been agreed between the Company of11.2 pence per share 2012: 10.0 pence.
Under the deficit 6% Dividend cover for the underlying business recovery plan, payments will increase before adjusting items was 6.1 times forthe three years to March 2015 by the 2012: 6.2 times.
greater of 10 percent or the percentage Net assets increase in dividend per share.
Thereafter, Balance sheet the payment will increase by 3.05% per Net assets rose from 127.1 million to annum.
The payment in 2012 13, the first 137.7m 137.7 million in the year.
year of the new plan, was 5.0 million.
8% Net working capital excluding derivative Cash financial instruments, contingent Adjusted earnings before interest, consideration and tax payable receivable tax, depreciation and amortisation increased by 2.9 million in the year to EBITDA increased by 11.7% to 18.8 million.
Trading working capital, Inventory turns increased by 0.1 to 3.3 which we define as inventory plus trade while debtor days reduced from 53 days debtors less trade creditors and customer to 51 days.
deposits as a percentage of sales, was 16.6% 2012: 15.4%.
Acquisitions and disposals On 17 December 2012 the Group acquired Cash generated from operations was Asylum Research Corporation for an 50.4 million, a reduction of 0.1 million initial consideration of $32 million.
The ratio of operating acquisition was funded from the Groups cash to operating profit, which is one of own cash resources.
our Key Performance Indicators, was 84.7% 2012: 110.5%.
Pensions The Group has defined benefit pension Net cash at the year end was 39.2 million schemes in the UK and the US.
The Group maintains been closed to new entrants since 2001 a committed Revolving Credit Facility and closed to future accrual from July with a club of three banks.
The total deficit, before tax, under which extends to December 2014, is for IAS 19 on these pension schemes rose in 50 million and is extendable to 70 million the year by 12.7 million to 47.9million by mutual consent.
In addition, the Group with a corresponding deferred tax asset has overdraft and other facilities totalling of 11.4 million.
In March 2013 the Group agreed Business Overview Business Review Corporate Governance Financial Statements Company Information 25 Oxford Instruments plc Report and Financial Statements 2013 a committed facility with the European The diverse nature of the Group combined Forward-looking statements Investment Bank to fund R&D in Europe.
with its current financial strength provides This document contains certain forwardThe facility, which can be drawn down asolid foundation for a sustainable looking statements.
The forward-looking atany time before December 2013, is business.
The Directors have reviewed statements reflect the knowledge and for25 million and can be either fixed the Groups forecasts and flexed them information available to the Company orfloating rate with a duration of up toincorporate a number of potential during the preparation and up to the toseven years.
scenarios relating to changes in trading publication of this document.
The Directors believe that very nature, these statements depend Employees the Group will be able to operate within upon circumstances and relate to events The average number of people employed its existing debt facilities.
This review that may occur in the future thereby during the year was 1,927, an increase of alsoconsidered hedging arrangements involving a degree of uncertainty.
As a result of the inplace.
As a consequence, the Directors Therefore, nothing in this document acquisition of Asylum, 74 employees believe that the Group is well placed to should be construed as a profit forecast joined the Group.
manage its business risks successfully.
Going concern The Financial Statements have been The Groups business activities, together prepared on a going concern basis, based Kevin Boyd with the factors likely to affect its future on the Directors opinion, after making Group Finance Director development, performance and position, reasonable enquiries, that the Group 11 June 2013 are set out in the Chief Executives hasadequate resources to continue Statement.
The financial position of the inoperational existence for the Group, its cash flows, liquidity position foreseeable future.
and borrowing facilities are described inthis Financial Review.
Investment in research and development R&D Total cash spend on R&D in the year was 25.1 million or 7.2% of sales 2012:23.7million, 7.0%.
A reconciliation between the amounts charged to the Income Statement and the cash spent is given below: 2013 2012 m m R&D expense charged to the consolidated statement of income 24.3 25.8 Less: depreciation of R&D related fixed assets 0.7 0.2 Add: amounts capitalised as fixed assets 0.8 0.9 Less: amortisation of R&D costs capitalised as intangibles 3.9 5.2 Add: amounts capitalised as intangible assets 4.6 2.4 Total cash spent on R&D during the year 25.1 23.7 The net book value of capitalised development costs at the end of the financial year was 12.3 million 2012: 11.7 million.
